s1pr2 (Proteintech)
Proteintech is a verified supplier 
94
Structured Review
Proteintech
s1pr2
S1pr2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 74 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s1pr2/S1PR2+Antibody/pm41667044-61-7-11
Average 94 stars, based on 74 article reviews
S1pr2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 74 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s1pr2/S1PR2+Antibody/pm41667044-61-7-11
Average 94 stars, based on 74 article reviews
s1pr2 - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Western Blot:Article Title: Hyperammonemia increases the release of pathological extracellular vesicles from monocytes by impairing lysosomal function and autophagy through the TNFα–cAMP–PKA–LC3 pathway Article Snippet: .. The hippocampal slices were homogenized and analyzed by Western blot as described above, using the following primary antibodies: GluaA1 (Glutamate A1 Subunit of Ampa Receptors, 1:1,000, Millipore, #04-855), GluA2 (Glutamate A2 Subunit of AMPA Receptors, 1:2,000, Proteintech, #11994-1-AP), IL-1R (Interleukin 1-Beta Receptor, 1:500, Abcam, AB106278 ), NR2A (2A subunit of NMDA receptors, 1:1,000, Millipore, #04-901), NR2B (2B subunit of NMDA receptors, 1:1,000, Millipore, #06-600), TNFR1 (1:1,000, Abcam, #ab19139), TrkB (1:500, Abcam, #ab18987), and SDS-Gel:Article Title: The novel sphingosine-1-phosphate receptor modulator KRP-203 prevents myocardial ischemia–reperfusion injury by preserving mitochondrial function through activation of the RISK and SAFE signaling pathways Article Snippet: Protein from cells or tissues was extracted using a Membrane and Cytosol Protein Extraction Kit (Beyotime, #P0033), followed by protein quantification using the BCA method. .. The samples were then denatured by heat, loaded onto a 10% SDS gel, separated by SDS–PAGE, transferred to PVDF membranes, and blocked with 1% BSA solution for 1 h. These membranes were treated with primary antibodies (S1P1/EDG1 (1:1000, Abcam, #ab259902), Control:Article Title: Hyperammonemia increases the release of pathological extracellular vesicles from monocytes by impairing lysosomal function and autophagy through the TNFα–cAMP–PKA–LC3 pathway Article Snippet: .. Primary antibodies used were against Alix (1:500, ProteinTech, #12422-1-AP), BDNF (brain-derived neurotrophic factor, 1:1,000, Invitrogen, #OSB00017W), Cathepsin-L (1:200, R&D #AF1515), CCL2 (1:2,000, Proteintech, #66272-1), Flotillin-2 (1:500, Invitrogen, #PA5-17178), IL-1β (1:500, RD Systems, #AF-501-NA), LAMP2 (1:200, Novus Biologicals, #NB300-591), LC3 (microtubule-associated protein 1A/1B-light chain 3, 1:1,000, Novus Biologicals, NB100-2220), Blocking Assay:Article Title: Ticagrelor attenuates cholestasis-induced liver fibrosis by inhibiting S1PR2-dependent Akt/ERK signaling, NLRP3 inflammasome activation. Article Snippet: S1PR2 activation is a pivotal player in chronic liver disease (CLD) progression through bile acid (BA) and sphingosine-1-phosphate (S1P) signaling.. This signaling promotes ductular reaction (DR), NLRP3 inflammasomedriven inflammation, and fibrosis progression, making S1PR2 antagonism a promising therapeutic approach.. Using structure-based virtual screening, Ticagrelor (TG) was identified as a potential S1PR2 inhibitor, demonstrating a strong predicted binding affinity (− 10.1 kcal/mol) and stable interactions with key residues Thr 21, Arg 33, Asn 89, and His 271. Membrane:Article Title: Ticagrelor attenuates cholestasis-induced liver fibrosis by inhibiting S1PR2-dependent Akt/ERK signaling, NLRP3 inflammasome activation. Article Snippet: S1PR2 activation is a pivotal player in chronic liver disease (CLD) progression through bile acid (BA) and sphingosine-1-phosphate (S1P) signaling.. This signaling promotes ductular reaction (DR), NLRP3 inflammasomedriven inflammation, and fibrosis progression, making S1PR2 antagonism a promising therapeutic approach.. Using structure-based virtual screening, Ticagrelor (TG) was identified as a potential S1PR2 inhibitor, demonstrating a strong predicted binding affinity (− 10.1 kcal/mol) and stable interactions with key residues Thr 21, Arg 33, Asn 89, and His 271. Incubation:Article Title: Ticagrelor attenuates cholestasis-induced liver fibrosis by inhibiting S1PR2-dependent Akt/ERK signaling, NLRP3 inflammasome activation. Article Snippet: S1PR2 activation is a pivotal player in chronic liver disease (CLD) progression through bile acid (BA) and sphingosine-1-phosphate (S1P) signaling.. This signaling promotes ductular reaction (DR), NLRP3 inflammasomedriven inflammation, and fibrosis progression, making S1PR2 antagonism a promising therapeutic approach.. Using structure-based virtual screening, Ticagrelor (TG) was identified as a potential S1PR2 inhibitor, demonstrating a strong predicted binding affinity (− 10.1 kcal/mol) and stable interactions with key residues Thr 21, Arg 33, Asn 89, and His 271. |
